Ubs Group Ag Caribou Biosciences, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 157,318 shares of CRBU stock, worth $294,184. This represents 0.0% of its overall portfolio holdings.

Number of Shares

157,318

Previous 106,536 47.67%

Holding current value

$294,184

Previous $174,000 75.86%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.56 - $2.73 $79,219 - $138,634	50,782 Added 47.67%	157,318 $306,000
Q2 2024 Aug 13, 2024	SELL	$1.62 - $5.05 $488,817 - $1.52 Million	-301,739 Reduced 73.91%	106,536 $174,000
Q1 2024 May 13, 2024	BUY	$4.82 - $8.26 $394,015 - $675,221	81,746 Added 25.03%	408,275 $2.1 Million
Q4 2023 Feb 09, 2024	BUY	$3.58 - $6.25 $626,582 - $1.09 Million	175,023 Added 115.52%	326,529 $1.87 Million
Q3 2023 Nov 09, 2023	BUY	$4.08 - $8.14 $145,362 - $290,011	35,628 Added 30.75%	151,506 $724,000
Q2 2023 Aug 11, 2023	SELL	$4.04 - $5.47 $96,463 - $130,607	-23,877 Reduced 17.08%	115,878 $492,000
Q1 2023 May 12, 2023	SELL	$4.3 - $7.78 $236,052 - $427,090	-54,896 Reduced 28.2%	139,755 $742,000
Q4 2022 Feb 08, 2023	BUY	$5.57 - $11.01 $811,821 - $1.6 Million	145,749 Added 298.04%	194,651 $1.22 Million
Q3 2022 Nov 10, 2022	BUY	$5.34 - $12.79 $187,193 - $448,353	35,055 Added 253.16%	48,902 $515,000
Q2 2022 Aug 10, 2022	SELL	$5.1 - $9.74 $9,149 - $17,473	-1,794 Reduced 11.47%	13,847 $75,000
Q1 2022 May 16, 2022	SELL	$8.42 - $15.32 $19,307 - $35,128	-2,293 Reduced 12.79%	15,641 $143,000
Q4 2021 Feb 14, 2022	BUY	$14.59 - $23.26 $130,959 - $208,781	8,976 Added 100.2%	17,934 $271,000
Q3 2021 Nov 15, 2021	BUY	$15.75 - $30.29 $141,088 - $271,337	8,958 New	8,958 $214,000

Others Institutions Holding CRBU

# of Institutions

135

Shares Held

52.6M

Call Options Held

148K

Put Options Held

70.7K

View Full List

About Caribou Biosciences, Inc.

Ticker CRBU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,840,800
Market Cap $114M
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...

More about CRBU

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account